Dermatology · Fremont, CA
Dermatology and skin studies in Fremont, CA
17 recruiting studies have a site in Fremont.
17 recruiting studiesSource: ClinicalTrials.gov, refreshed October 26, 2026How we list studies
Studies
- RecruitingHealthy volunteersPhase 1
A 3-part Study of SYX-5219 in Healthy Volunteers and Participants With Atopic Dermatitis
Sitryx Therapeutics Ltd
- Location
- Fremont, CA + 5 other US sites
- Eligibility basics
- Ages 18–65
- RecruitingPhase 3
Phase 3 Study of Denifanstat in Participants With Moderate to Severe Acne (AURORA)
Sagimet Biosciences Inc.
- Location
- Fremont, CA + 17 other US sites
- Eligibility basics
- Ages 12+
- RecruitingPhase 3
Long-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRAGMATYK)
Bristol-Myers Squibb
- Location
- Fremont, CA + 90 other US sites
- Eligibility basics
- Ages 40+
- RecruitingPhase 3
An Extension Study to Assess Safety and Efficacy of Remibrutinib in Participants With Moderate to Severe HS
Novartis Pharmaceuticals
- Location
- Fremont, CA + 20 other US sites
- Eligibility basics
- Ages 18–100
- RecruitingPhase 1
A Trial to Test the Safety and Efficacy of TEV-53408 in Participants With Vitiligo
Teva Branded Pharmaceutical Products R&D LLC
- Location
- Fremont, CA + 2 other US sites
- Eligibility basics
- Ages 18–75
- RecruitingPhase 3
Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib
Incyte Corporation
- Location
- Fremont, CA + 73 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 2
A Study of LY4005130 in Adult Participants With Severe Alopecia Areata (Hair Loss)
Eli Lilly and Company
- Location
- Fremont, CA + 8 other US sites
- Eligibility basics
- Ages 18–60
- RecruitingPhase 2
A Study of LY4005130 in Adult Participants With Non-Segmental Vitiligo
Eli Lilly and Company
- Location
- Fremont, CA + 17 other US sites
- Eligibility basics
- Ages 18–75
- RecruitingPhase 2
A Study of Zasocitinib in Adults With Nonsegmental Vitiligo
Takeda
- Location
- Fremont, CA + 20 other US sites
- Eligibility basics
- Ages 18–75
- RecruitingPhase 2
Study of ENV-294 in Adults With Moderate-to-Severe Atopic Dermatitis
Enveda Therapeutics
- Location
- Fremont, CA + 29 other US sites
- Eligibility basics
- Ages 18–75
- RecruitingPhase 3
Open Label Study to Investigate the Safety and Efficacy of Ponesimod in Moderate-to-Severe Chronic Plaque Psoriasis
Vanda Pharmaceuticals
- Location
- Fremont, CA + 9 other US sites
- Eligibility basics
- Ages 18–65
- RecruitingPhase 2
Study of the Efficacy and Safety of ICP-332 in Participants With Prurigo Nodularis
Beijing InnoCare Pharma Tech Co., Ltd.
- Location
- Fremont, CA + 13 other US sites
- Eligibility basics
- Ages 18–75
- RecruitingPhase 4
A Study to Investigate the Effectiveness of Tirzepatide (LY3298176) Following Initiation of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque PsO and Obesity or Overweight in Clinical Practice…
Eli Lilly and Company
- Location
- Fremont, CA + 38 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
A Study to Evaluate the Efficacy, Safety, and Drug Levels of Deucravacitinib (BMS-986165) in Adolescent Participants With Moderate to Severe Plaque Psoriasis
Bristol-Myers Squibb
- Location
- Fremont, CA + 26 other US sites
- Eligibility basics
- Ages 12–17
- RecruitingPhase 3
A Study to Evaluate the Efficacy and Safety of Bimekizumab in Study Participants With Palmoplantar Pustulosis
UCB Biopharma SRL
- Location
- Fremont, CA + 7 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 2
Evaluate Efficacy and Safety of Repeat Subcutaneous Doses of FB825 in Adults With Moderate-to-Severe Atopic Dermatitis
Oneness Biotech Co., Ltd.
- Location
- Fremont, CA + 5 other US sites
- Eligibility basics
- Ages 18–65
- RecruitingPhase 3
Study to Evaluate the Efficacy and Safety of Deuruxolitinib in Adolescents With Severe Alopecia Areata
Sun Pharmaceutical Industries, Inc.
- Location
- Fremont, CA + 53 other US sites
- Eligibility basics
- Ages 12–17
Who these studies look for
Most require an active, diagnosed skin condition of a certain severity and a pause on some current treatments before starting.
Matching a page like this one never means you qualify. Each research team decides eligibility at screening.